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Transmission of prions between species is limited by the ‘‘species barrier,’’ which hampers a full characterization of
human prion strains in the mouse model. We report that the efficiency of primary transmission of prions from
Creutzfeldt–Jakob disease patients to a wild rodent species, the bank vole (Clethrionomys glareolus), is comparable to
that reported in transgenic mice carrying human prion protein, in spite of a low prion protein–sequence homology
between man and vole. Voles infected with sporadic and genetic Creutzfeldt–Jakob disease isolates show strain-
specific patterns of spongiform degeneration and pathological prion protein–deposition, and accumulate protease-
resistant prion protein with biochemical properties similar to the human counterpart. Adaptation of genetic
Creutzfeldt–Jakob disease isolates to voles shows little or no evidence of a transmission barrier, in contrast to the
striking barriers observed during transmission of mouse, hamster, and sheep prions to voles. Our results imply that in
voles there is no clear relationship between the degree of homology of the prion protein of the donor and recipient
species and susceptibility, consistent with the view that the prion strain gives a major contribution to the species
barrier. The vole is therefore a valuable model to study human prion diversity and, being susceptible to a range of
animal prions, represents a unique tool for comparing isolates from different species.
Citation: Nonno R, Di Bari MA, Cardone F, Vaccari G, Fazzi P, et al. (2006) Efficient transmission and characterization of Creutzfeldt–Jakob disease strains in bank voles. PLoS
Pathog 2(2): e12.
Introduction
Transmissible spongiform encephalopathies (TSEs) are a
group of fatal neurodegenerative diseases of humans and
animals, caused by unconventional infectious agents known
as prions. They are characterized by the accumulation of a
disease-associated isoform (PrP
Sc) of the host-encoded cel-
lular prion protein (PrP
C). According to the protein-only
hypothesis, prions are composed mainly or exclusively of
PrP
Sc. Although apparently devoid of any nucleic acid, prions
exist as different infectious strains with characteristic
pathogenetic properties [1], which can be characterized from
their different disease phenotypes in an inbred animal host.
The prion hypothesis equates strains to different self-
propagating conformational variants of PrP
Sc [2], which
parallel the diversity of physicochemical properties of PrP
Sc
observed in human and animal prion diseases [3–6]. The
electrophoretic mobility and the relative level of glycosyla-
tion of the protease-resistant fragment of PrP
Sc are the basis
for the molecular classiﬁcation of TSEs.
Sporadic Creutzfeldt–Jakob disease (sCJD) represents the
most common human TSE [7], occurring worldwide with an
incidence of about 1.7 cases per million people per year [8],
and has an apparently spontaneous origin. Genetic Creutz-
feldt–Jakob disease (gCJD) [9] is associated with mutations of
the prion protein–gene and accounts for about 10% of
Creutzfeldt–Jakob disease (CJD) cases [8]. Other genetic TSEs
are Gerstmann–Stra ¨ussler–Scheinker disease (GSS) and fatal
familial insomnia. The emergence of variant Creutzfeldt–
Jakob disease (vCJD) [10], a new disease linked to bovine
spongiform encephalopathy (BSE) [11,12], highlights the
zoonotic potential of TSEs.
Prion diversity is revealed by transmission to laboratory
animals, but this approach can be seriously limited by the
‘‘species barrier’’ effect, which hampers a full character-
ization of human prion strains in the mouse model [11,13].
Animal models that are suitable for studies with sCJD or gCJD
therefore represent a major advance in understanding the
extent to which various clinico-pathological forms represent
different strains, and whether atypical forms are caused by
novel prion strains.
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the degree of PrP sequence homology is responsible for the
species-barrier effect [14], a number of studies since then, in
addition to the results reported here, have challenged this
view [11,15,16]. The main strategy for overcoming the species
barrier from human to mice has been the generation of
transgenic mouse lines over-expressing human PrP or
chimeric mouse–human PrP [2,17–22]. Such mice usually
propagate human prions more efﬁciently than wild-type
mice, although with variable results depending on the prion
strain. For example, vCJD transmits more readily to wild-type
mice than to the humanized transgenic models. Recently, the
term ‘‘transmission barrier’’ rather than ‘‘species barrier’’ has
been proposed to account for the variable ability of prion
strains to cross barriers between species [23]. To improve on
the traditional mouse-based model and to deepen our
understanding of the species barrier, we carried out trans-
mission studies of human prions to the bank vole (Clethrion-
omys glareolus), a wild rodent species which has proved to be
susceptible to prions from a range of sources [24] (U. Agrimi
et al., unpublished data).
Results
Voles Are Susceptible to Human Prions
In sCJD, the PrP genotype at position 129, codifying for
methionine (M) or valine (V), and the electrophoretic
mobility of the protease-resistant unglycosylated fragment
of PrP
Sc (21 kDa for type 1 and 19 kDa for type 2) are
correlated with disease phenotype and are the basis for the
classiﬁcation of sCJD into six distinct subtypes: MM1/MV1,
VV2, MV2, MM2, MM2-thalamic, and VV1 [25]. The efﬁciency
of transmission of sCJD to voles and mice varied according to
different subtypes. Voles were highly susceptible to MM1 and
MV1 sCJD, with all voles succumbing to disease after short
survival times (Table 1). Voles inoculated with MM2 sCJD
succumbed to disease with longer survival times (Table 1),
while MV2 and VV2 sCJD did not induce disease up to 500 d
after inoculation. The emerging picture is in agreement with
recent ﬁndings in humanized transgenic models, showing a
general tendency of MM1/MV1 sCJD to transmit with higher
attack rates and shorter incubation times than type 2 cases
[19,20,21]. Intriguingly, this phenomenon appears to parallel
disease duration in human sCJD cases, in that type 2 cases are
usually associated with longer survival times than type 1 cases
[26].
Voles were also highly susceptible to prions from gCJD
cases associated with the PrP mutations V210I and E200K
(Table 1). By contrast, the P102L GSS case has not given rise
to clinical disease up to 500 d after inoculation. In
comparison with human TSEs, the prototype mouse-passaged
scrapie strain ME7 transmitted with a mean survival time that
was intermediate between type 1 and type 2 CJD cases (Table
1).
C3H mice were less susceptible than voles to all human
cases inoculated (Table 1). Mice did not show obvious clinical
signs and were sacriﬁced or died at ages typical for
uninoculated mice. However, based on PrP
Sc accumulation
assessed by Western blot and/or spongiform changes assessed
by histopathology, 40%–50% of mice surviving for more than
250 d after inoculation with MM1/MV1 sCJD, MM2 sCJD, and
V210I gCJD showed unequivocal signs of prion infection and
were thus considered infected (unpublished data). These
results are similar to those previously reported for primary
transmissions of MM1 sCJD to other mouse strains [11]. By
contrast, MV2 sCJD, VV2 sCJD, E200K gCJD, and GSS did not
show evidence of transmission in any recipient mice.
Some CJD Isolates Adapt to Voles with Little or No
Evidence of Transmission Barrier
The transmission-barrier effect appears to consist of
several different elements: a low efﬁciency of infection, the
selection of agent strains that replicate more rapidly in the
new species, and differences in pathogenesis between
interspecies and intraspecies transmissions. The extent of a
transmission barrier can be inferred by the decrease in
survival time between the primary transmission and sub-
sequent passage in the new host species. To investigate
whether the ease of transmission of certain human TSEs to
voles is the result of a low transmission barrier, we set up
secondary transmissions. MM1 and MV1 sCJD gave similar
mean survival times of ;130 d post-inoculation (Table 1),
with a signiﬁcant shortening of ;30% compared to primary
transmission. In comparison, MM2 sCJD gave a long
incubation period on the second passage as well as on the
ﬁrst passage (Table 1), with only a slight decrease compared
with the ﬁrst passage. Intriguingly, secondary transmission of
E200K or V210I gCJD gave no signiﬁcant decrease in survival
time compared to the primary transmission (Table 1),
suggesting that the efﬁciency of transmission of gCJD was
not affected by a human–vole species barrier. On the other
hand, the mouse-passaged scrapie strain ME7 encountered a
striking transmission barrier and adapted to voles as a very
fast strain (Table 1).
PrP
Sc Produced in CJD-Infected Voles Has Similar
Molecular Features to the Corresponding Human Inocula
All voles succumbing to prion diseases accumulated high
levels of protease-resistant PrP
Sc in their brains. We studied
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Synopsis
Prions are unconventional infectious agents that cause fatal
neurodegenerative diseases. The transmission of prions between
species is considered a rare event because it is limited by the
‘‘species barrier.’’ Nevertheless, in the past 10 y, more than 180
people worldwide died with variant Creutzfeldt–Jakob disease
(vCJD) following consumption of bovine spongiform encephalop-
athy (BSE)–contaminated food. The vCJD crisis highlights the need
for experimental approaches that are able to characterize human
prions and to estimate the risk of animal prions for man. The authors
used a new animal model, the bank vole, which appears to address
these issues. They observed that these rodents are highly
susceptible to sporadic Creutzfeldt–Jakob disease (sCJD) and
genetic Creutzfeldt–Jakob disease (gCJD), as well as to several
animal prions. Transmission to voles indicates that sCJD is caused by
at least two distinct prion strains. Surprisingly, voles challenged with
gCJD isolates do not show a species barrier, while prions from
closely related rodent species encounter a clear barrier in trans-
mitting to voles. Inoculation of voles with scrapie-related and BSE-
related strains from several species suggests that the prion strain,
and not the donor species, is the major determinant of prion
transmissibility between different species. The authors conclude
that the vole model is a valuable tool for comparing animal and
human prions.the biochemical characteristics of human and vole PrP
Sc by
comparing their electrophoretic mobility and glycoform
pattern after protease digestion (Figure 1). Voles inoculated
with type 1 human PrP
Sc (MM1 sCJD, MV1 sCJD, E200K gCJD,
V210I gCJD) accumulated PrP
Sc with a protease-resistant
unglycosylated fragment of the same size as the human
counterpart (Figure 1A). In MM2 sCJD, the molecular weight
of both human and vole unglycosylated PrP
Sc was of type 2,
;2 kDa lower than type 1 (Figure 1A). These PrP
Sc molecular
patterns were unchanged after vole-to-vole transmission
(Figure 1B). As the size of the protease-resistant unglycosy-
lated fragment is believed to reﬂect the conformation of
PrP
Sc [2], these ﬁndings show that the subtype-speciﬁc
conformations of human PrP
Sc have been faithfully repro-
duced in voles. Interestingly, the molecular weight of this
PrP
Sc fragment from voles inoculated with the mouse-
adapted scrapie strain ME7 was intermediate between types
1 and 2 (Figure 1A, 1B, and 1D).
The relative amounts of the three major bands observed on
immunoblot further characterizes subtype-speciﬁc PrP
Sc
fragments [4,25,27]. The glycoform pattern of the human
PrP
Sc was characterized by the expected dominance of the
mono-glycosylated PrP
Sc fragment in sCJD and V210I gCJD,
while E200K gCJD had similar levels of di-glycosylated and
mono-glycosylated PrP
Sc fragments [27] (Figure 1A and 1C).
Vole PrP
Sc was generally more glycosylated than human
PrP
Sc. MM2 sCJD–affected voles showed similar levels of di-
glycosylated and mono-glycosylated PrP
Sc fragments, while
di-glycosylated PrP
Sc was dominant in voles with MM1/MV1
sCJD and gCJD (Figure 1A and 1C). Similar changes in the
glycosylation pattern associated with the same strain after
transmission to mice have been reported [12,21]. The glyco-
form pattern of PrP
Sc in voles inoculated with ME7 was
different from that obtained in voles inoculated with all
human cases, being characterized by the highest proportion
of di-glycosylated PrP
Sc (Figure 1C).
Lesion Profiles and PrP
Sc Deposition in Voles Show
Subtype-Specific Patterns
Spongiform neurodegeneration was the most prominent
ﬁnding in voles affected with CJD, accompanied by gliosis and
neuronal loss (Figure S1). These changes were localized in
speciﬁc brain regions with little variability amongst individ-
ual voles. In voles with sCJD and gCJD, caudal brain regions
were mainly spared.
To characterize the disease phenotype of affected voles, we
analyzed the patterns of vacuolar degeneration in selected
areas of the brain, as represented by the ‘‘lesion proﬁle’’
(Figure 2). The lesion proﬁle is a well-established semi-
quantitative method for representing the targeting of
vacuolation to different brain regions, and reliably discrim-
inates between TSE strains in mice [11,28]. The MM1 sCJD,
MV1 sCJD, V210I gCJD, and E200K gCJD cases produced
identical patterns of vacuolar degeneration in voles (Figure
2A), characterized by grey-matter spongiform degeneration
of the superior colliculi, thalamic nuclei, and hippocampus,
and the retrosplenial and cingulate cortices. The medulla
oblongata was less severely involved, while the cerebellum,
hypothalamus, and septum showed only occasional vacuola-
tion. Voles infected from the MM2 sCJD case (Figure 2B)
displayed a pattern of vacuolation in the medulla, cerebellum,
and thalamus similar to that observed with MM1/MV1 sCJD,
but their lesion proﬁle was characterized by a lower spongi-
form change in the hippocampus and cortices, while septal
nuclei were more severely involved. Voles inoculated with
mouse scrapie ME7 (Figure 2B) had a distinct lesion proﬁle
characterized by severe vacuolation of the hypothalamus,
which was mainly spared by human prions.
Spongiform changes in positive mice with MM1 sCJD, MV1
sCJD, and V210I gCJD were generally mild, and this was
consistent with the absence of clinical disease. The lesion
proﬁles paralleled those observed in voles (Figure 2D) and are
Table 1. Survival Times of Voles and C3H Mice Infected with Human TSEs
Inoculum Voles C3H Mice
Survival Time (Days 6 SD) Clinical Disease Survival Time (Days 6 SD)
a Clinical Disease Infection
b
MM1 sCJD 188 6 22 16/16 258–774 0/7 3/7
Vole-passaged MM1 sCJD 129 6 8 14/14
Mouse-passaged MM1 sCJD 188 6 17 9/9 450–815 0/9 3/9
MV1 sCJD 179 6 10 20/20 290–695 0/7 3/7
Vole-passaged MV1 sCJD 128 6 15 15/15
Mouse-passaged MV1 sCJD 187 6 33 8/8 351–872 0/13 0/13
MM2 sCJD 408 6 80 9/9 555–796 0/8 4/8
Vole-passaged MM2 sCJD 339 6 27 20/20
MV2 sCJD .500 0/20 367–871 0/7 0/7
VV2 sCJD .500 0/18 582–862 0/8 0/8
E200K/MM1 gCJD 158 6 13 19/19 533–686 0/4 0/4
Vole-passaged E200K gCJD 143 6 12 13/13
V210I/MM1 gCJD 157 6 8 20/20 258–774 0/6 3/6
Vole-passaged V210I gCJD 151 6 24 12/12
P102L/MM1 GSS .500 0/20 546–774 0/4 0/4
ME7 230 6 46 7/7 169 6 6 22/22
Vole-passaged ME7 83 6 8 13/13
aWhen mice did not show clinical signs, the range of survival time is reported.
bPrion infection in clinically healthy mice that died or were sacrificed at more than 250-d post-inoculation was assessed by Western blotting or histopathology.
MM, MV, or VV indicate genotype at codon 129; 1 or 2 indicate the molecular types, classified according to Parchi et al. [3]; SD, standard deviation.
DOI: 10.1371/journal.ppat.0020012.t001
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Transmission of Human Prions to Volesin agreement with previous reports of sCJD-infected mice
[11,29].
Analysis of the distribution of PrP
Sc in the brain, assessed
by parafﬁn-embedded tissue (PET) blot (Figure 3), further
strengthened the similarity of type 1 sCJD and gCJD, which
showed indistinguishable patterns of PrP
Sc accumulation,
primarily in the cerebral cortex, striatum, thalamus, sub-
stantia nigra, hippocampus, and in the nuclei of the visual
pathways. On the other hand, MM2 sCJD was characterized by
as t r o n g e rP r P
Sc accumulation in the septum, lateral
habenular nuclei, and hypothalamus, with only sparse label-
ing in the cerebral cortex and striatum. Immunohistochem-
istry for PrP
Sc showed mainly a punctate or synaptic staining
in type 1 sCJD and in gCJD, while MM2 sCJD was
characterized by a coarse, mostly intracellular, pattern and
by frequent staining of the rim of vacuoles (Figure S1).
C3H Mice Do Not Show Disease upon Serial Passage of
sCJD, but Propagate Infectivity with Strain Properties
Identical to the Original Human Inocula
During adaptation to a new host, prions can either
maintain their original strain properties, as assessed by
passage back into the original species, or can change in a
manner consistent with the isolation of variant strains with
shorter incubation periods in the new host [30]. In an attempt
to adapt sCJD to C3H mice, we set up secondary transmission
experiments. C3H mice infected with mouse-passaged MM1
sCJD and MV1 sCJD did not show clinical signs of prion
disease and died or were sacriﬁced after long survival times
(Table 1). Only three out of nine mice inoculated with mouse-
passaged MV1 sCJD had low levels of PrP
Sc (unpublished
data), while none of the mice inoculated with MM1 sCJD
showed evidence of prion infection. However, in another
study of MM1 sCJD in different mouse strains, it was possible
to transmit infection from mouse to mouse, but the
incubation periods remained extremely long (M. Bruce,
unpublished data). Lack of adaptation after successful
primary transmission was unexpected, although a similar
phenomenon was recently reported [22] in transgenic mice
expressing human PrP with V at codon 129 infected with BSE.
Our ﬁndings suggest that C3H mice propagate sCJD prions at
a level insufﬁcient for sustaining the disease upon serial
passage.
To address this hypothesis, we inoculated bank voles with
the same mouse-passaged sCJD used for secondary trans-
missions in mice. Voles had very short survival times (188 and
187 d post-infection [dpi], respectively; see Table 1) and a
100% attack rate, showing that the brains of mice inoculated
with sCJD contained high levels of infectivity, incompatible
with persistence of the original human inoculum. Strikingly,
Figure 1. Determination of the Molecular Type of PrP
Sc Produced in Voles following Transmission of sCJD and gCJD
(A) Immunoblot of proteinase K–resistant PrP
Sc from sCJD and gCJD subtypes in human patients and after first passage in voles. PrP
Sc produced in voles
after primary transmission of mouse-passaged MM1 sCJD and MV1 sCJD, and of the mouse-adapted scrapie strain ME7 is also shown. The identity of the
brain sample is designated above each lane.
(B) Comparison of proteinase K–resistant PrP
Sc produced in voles following first and second passages of MV1 sCJD, MM2 sCJD, E200K gCJD, and V210I
gCJD. PrP
Sc produced in voles after first passage of the mouse-adapted scrapie strain ME7 is also shown. The identity of the brain sample is designated
above each lane.
(C) Scatter-graph of proportions of di-glycosylated and mono-glycosylated PrP
Sc in human patients (denoted by filled circles, filled inverted triangles,
filled diamonds, filled squares, and filled upright triangles) and voles (denoted by open circles, open inverted triangles, open diamonds, open squares,
open upright triangles, and asterisks), with MM1 sCJD (denoted by filled squares and open squares), MV1 sCJD (denoted by filled diamonds and open
diamonds), MM2 sCJD (denoted by filled circles and open circles), V210I gCJD (denoted by filled inverted triangles and open inverted triangles), E200K
gCJD (denoted by filled upright triangles and open upright triangles), and ME7 (denoted by asterisks).
(D) Comparison of proteinase K–resistant PrP
Sc produced in voles following inoculation with MM1 sCJD, MM2 sCJD, and the mouse-adapted scrapie
strain ME7. Strep-tagged molecular markers (25 kDa and 20 kDa) are shown. The identity of the brain samples is designated above each lane.
DOI: 10.1371/journal.ppat.0020012.g001
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Transmission of Human Prions to Volesthe survival times, the biochemical characteristics of PrP
Sc,
and the brain-lesion proﬁles of voles inoculated with mouse-
passaged sCJD were identical to those observed after direct
transmission of the original sCJD isolates (Table 1; Figures 1A
and 2C). From these experiments, we conclude that a subset
of mice infected with type 1 sCJD propagated high levels of
infectious prions which carried strain-speciﬁc information
similar to that of the original human prions. Recently, several
experimental approaches have emphasized the possible
occurrence of a subclinical carrier-state in recipient animals,
after either prion interspecies [31,32] or intraspecies [33,34]
transmissions, and implications for public health have been
emphasized [23,35]. Our data add further concern because
they indicate that animals remaining clinically healthy after
interspecies transmission may replicate prions that transmit
inefﬁciently to individuals of the same species but are highly
infectious for a third species.
Transmission Barrier Depends on Prion Strain, rather than
PrP Homology
Differences in amino acid sequence between donor PrP
Sc
and recipient PrP
C have been proposed to be one of the main
factors contributing to prion species barriers [14]. However,
the reasons for the extraordinary sensitivity of voles to sCJD
and gCJD, compared to the low susceptibility of mice, are not
easily deduced from the comparison of PrP sequences (Figure
4). Indeed, the prion proteins of voles and mice display high
homology and have several amino acid substitutions com-
pared to human PrP. Taking into consideration the central
portion of the PrP sequence, which has been proposed to play
a major role in determining the species barrier [17], the vole
and the mouse prion proteins differ at three positions, which
are Met
109Asn
154Asn
169 in the vole and Leu
108Tyr
153Ser
168 in
the mouse. The corresponding human positions are
Met
109His
154Ser
169, suggesting that homology at position
109 between the vole and the human PrP sequences might
play a role in the ease of transmission observed with some
human TSEs.
It is worth noting that all animal models suitable for the
study of sCJD and gCJD prions are Met at the corresponding
human residue 109. Even single amino acid substitutions at
this position of the prion protein can inﬂuence the efﬁciency
of transmission of prions to mice [36,37] and voles [24]. To
further evaluate the relative contributions of TSE agent
strain and PrP sequence homology in determining the
transmission barrier, we inoculated bank voles with scrapie-
related and BSE-related strains from species with different
PrP sequences, such as C57Bl mice, VM mice, hamsters, and
sheep (Figure 5). While the short survival times observed
overall in these transmission studies suggest that the high
susceptibility of voles to TSEs is not restricted to human
prions (Figure 5A), the decrease in survival time observed in
secondary transmissions implies that scrapie-related and
BSE-related strains, unlike gCJD, encounter a clear trans-
mission barrier in voles (Figure 5B).
Figure 2. Lesion Profiles in Voles and Mice following Transmission of sCJD and gCJD
Brain-scoring positions are medulla (1), cerebellum (2), superior colliculus (3), hypothalamus (4), thalamus (5), hippocampus (6), septum (7), retrosplenial
and adjacent motor cortex (8), and cingulate and adjacent motor cortex (9).
(A) Lesion profiles in voles infected with MM1 sCJD (denoted by open squares), MV1 sCJD (denoted by open circles), V210I gCJD (denoted by open
diamonds), and E200K gCJD (denoted by open upright triangles).
(B) Lesion profiles in voles infected with MM2 sCJD (denoted by open squares) and the mouse-passaged scrapie strain ME7 (denoted by open circles).
(C) Lesion profiles in voles infected with human sCJD (denoted by open squares and open circles) and mouse-passaged sCJD (denoted by open
diamonds and open upright triangles), MM1 sCJD (denoted by open squares and open diamonds), and MV1 sCJD (denoted by open circles and open
upright triangles).
(D) Lesion profiles in C3H mice infected with MM1 sCJD (denoted by open circles), MV1 sCJD (denoted by open upright triangles), and V210I gCJD
(denoted by open diamonds).
DOI: 10.1371/journal.ppat.0020012.g002
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Transmission of Human Prions to VolesThe extent of each transmission barrier was inferred by the
reduction in survival times between primary and secondary
transmissions (Figure 5C and 5D). The variable transmission
barriers observed with different prion strains from the same
donor species (Figure 5C) clearly point to the prion strain as a
determinant of the outcome of interspecies transmission in
bank voles, as opposed to PrP sequence homology with the
donor species. Conversely, the magnitude of the transmission
barrier varied according to the original source of the prion
isolate, irrespective of the donor species (Figure 5D).
Discussion
We studied the transmission characteristics of human
prions in a new animal model, the bank vole, which showed
an unforeseen susceptibility to sCJD and gCJD. Some
subtypes of sCJD and gCJD gave very short survival times
and faithful propagation of their molecular phenotype in
voles. These ﬁndings are unprecedented for wild-type animal
models and comparable to what has been reported in
humanized transgenic mouse lines. These features make the
vole model a valuable and inexpensive tool for in vivo
bioassays of the most common forms of sCJD and gCJD and
for the characterization of human prion strains in relation to
the clinico-pathological phenotype of patients. On this point,
we infer the existence of at least two different prion strains in
MM1/MV1 and MM2 sCJD, based on the survival times and the
disease phenotype observed after primary and secondary
transmission. The lack of transmission up to 500 dpi for MV2
and VV2 sCJD sources suggests that they could represent
further sCJD strains. Genetic CJD with V210I and E200K
mutations produced disease phenotypes similar to each other
and indistinguishable from that induced by type 1 sCJD, and
thus may be caused by a strain similar to the MM1/MV1
subtype. Overall, biological strain typing in voles concurs
with the clinico-pathological classiﬁcation of sCJD and gCJD
[25,38].
The transmission studies presented here recapitulate
several features of prion interspecies transmission, such as
variable transmission barriers with different strains from the
same donor species [11,15] and the occurrence of prion
infections in clinically healthy animals [31,32]. The suscept-
ibility of voles to different prion sources allowed us to study
several transmission barriers in a single animal model.
Surprisingly, V210I gCJD and E200K gCJD transmit in
secondary transmission with mean survival times similar to
the ﬁrst passage. These ﬁndings show that some prion strains,
but not all, could transmit to a different species (i.e., with a
different PrP sequence) in the absence of a species barrier.
Figure 3. Regional Distribution of Protease-Resistant PrP
Sc in Voles
following Transmission of sCJD and gCJD
PET blots of coronal sections of the forebrain (telencephalon in [A] and
diencephalon in [B]), midbrain (C), and hindbrain (D) in voles infected
with MM2 sCJD, MM1 sCJD, MV1 sCJD, V210I gCJD, and E200K gCJD. At
the lower part of the figure, the labeled coronal sections of a negative
control brain are shown. NC, neocortex; Sp, septum; St, striatum; Hp,
hippocampus; Th, thalamus; Hy, hypothalamus; SC, superior colliculus;
GN, geniculate nuclei; SN, substantia nigra; Cb, cerebellum; MO, medulla
oblongata.
DOI: 10.1371/journal.ppat.0020012.g003
Figure 4. Alignment of Human, Vole, and Mouse Prion Protein–Amino Acid Sequences
The sequence numbers of the human (Homo sapiens) amino acids are indicated and refer to the residue under the final digit. In the vole (C. glareolus)
and the mouse (Mus musculus) sequences, identical residues to the human are indicated as dots.
DOI: 10.1371/journal.ppat.0020012.g004
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Transmission of Human Prions to VolesScott and colleagues recently proposed that the majority of
the so-called species barriers are actually strain barriers [39].
Our results provide further evidence that the outcome of
interspecies transmission of prions cannot be predicted by
the degree of PrP sequence homology between two species,
but depends mainly on the prion strain. In fact, prion strains
coming from the same species display variable transmission
barriers in voles (Figure 5C) as reported in mice [15] and
transgenic models [16,20], consistent with the view that
sequence homology alone is not sufﬁcient to explain the
species-barrier effect. Furthermore, transmission barriers in
voles seem to vary according to the prion strain, and also
when a given strain is propagated in different species (Figure
5D). Several studies with mammalian and yeast prions point
to an intimate relationship between prion strains and
transmission barriers [16,40–42]. This interpretation is con-
sistent with recent studies with mammalian prion amyloids
[43] and yeast prions [44], which suggest that the PrP
sequence of any individual species dictates the range of
possible PrP conformations and hence the susceptibility to
different prion strains. In this context, it is possible to
speculate that the vole PrP sequence is particularly prone to
faithfully reproduce the conformation that characterizes
PrP
Sc of some human CJD strains, as supported by the fact
that gCJD cases do not encounter apparent transmission
barriers. It is, however, possible that mechanisms other than
the PrP primary sequence contribute to the species barrier,
for instance binding of PrP
C [45] or PrP
Sc [46,47] to other
proteins or to cellular factors. Transgenic mice expressing
vole PrP are being generated and will be challenged with
human prions in order to investigate whether the trans-
mission barrier encountered in voles depends on vole PrP
sequence or on other host factors.
Our ﬁndings also have important implications for public-
health issues related to the zoonotic potential of prion
diseases. The observation that prion infections in clinically
healthy individuals of one species may be highly infectious for
another species shows that a possible threat to human health
can derive from animals in which a prion infection could not
be easily detected by current diagnostic methods. Further-
more, the ﬁnding that prions can be transmitted between
species with different PrP sequences, in the absence of a
transmission barrier, underlines the difﬁculty of predicting
the impact on public health of ruminant TSEs, such as BSE,
BASE (bovine amyloidotic spongiform encephalopathy) [48],
scrapie, and chronic wasting disease. The vole model, being
susceptible to a range of prion strains, represents a major
advance for the characterization of TSE isolates from
different species and may aid in the development of control
strategies for TSEs.
Figure 5. Comparison of Transmission Barriers of Human, Sheep, Mouse, and Hamster Prions following Transmission to Voles
In (A–C), inocula are grouped according to the sequence homology of mature PrP between the donor species and voles, from the least to the most
divergent (golden hamster, 2.9% divergence; C57BL mouse strain, 2.9% divergence; VM mouse strain, 3.4% divergence; human, 7.1% divergence; and
sheep, 7.1% divergence). In (D), inocula are ranked according to the magnitude of the transmission barrier and are grouped according to the original
prion source.
(A) Survival times following first passage in voles of hamster-passaged scrapie strains 263K and 139H, C57BL mice-passaged BSE strain 301C, C57BL
mice-passaged scrapie strains ME7 and 139A, VM mice-passaged BSE strain 301V, VM mice-passaged scrapie strain 22A, human sCJD (MM1, MV1, and
MM2 subtypes) and gCJD (E200K and V210I subtypes), sheep-passaged BSE, and sheep natural scrapie isolates from the United Kingdom (SSUK) and
Italy (SSIT); error bars represent standard deviation.
(B) Survival times following second passage in voles of the same transmissions as in (A); error bars represent standard deviation.
(C and D) The magnitude of each transmission barrier is calculated as the ratio of mean survival times observed following first and second passage (a
value of 1 denotes an absence of transmission barrier).
DOI: 10.1371/journal.ppat.0020012.g005
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Animals. The research protocol has been approved by the Service
for Biotechnology and Animal Welfare of the Istituto Superiore di
Sanita ` and authorized by the Italian Ministry of Health, according to
Legislative Decree 116/92, which has implemented in Italy the
European Directive 86/609/EEC on laboratory animal protection.
Bank voles (Istituto Superiore di Sanita ` breeding colony) and C3H
mice (Charles River, Como, Italy) were housed in standard cages and
treated according to Legislative Decree 116/92 guidelines, and animal
welfare was routinely checked by veterinarians from the Service for
Biotechnology and Animal welfare. All animals were individually
identiﬁed by a passive integrated transponder.
Brain inocula. Patient CJD diagnoses were conﬁrmed by histo-
pathology, immunohistochemistry, and Western blotting [27]. Human
brain samples for transmission were collected from areas showing
pathology and PrP
Sc accumulation, and stored at 80 8C.
For natural sheep scrapie isolates, frozen brain tissue from the
medulla oblongata was obtained from one Sarda sheep (Italy) and one
Suffolk sheep (United Kingdom) carrying the ARQ/ARQ (indicating
amino acids at codons 136, 154, and 171, respectively, on both alleles)
PrP genotype. Brain tissue from the United Kingdom scrapie case
(PG671/97) was provided by the Veterinary Laboratory Agency
(Weybridge, United Kingdom).
Brain tissue from a Cheviot sheep (AHQ/AHQ) experimentally
infected with BSE was obtained from the Neuropathogenesis Unit at
the Institute for Animal Health.
Mouse-passaged TSE strains were supplied by the TSE Resource
Centre, Institute for Animal Health; hamster-passaged scrapie strains
were originally donated by R. H. Kimberlin (Institute for Animal
Health).
The inocula from mouse-adapted and hamster-adapted TSE strains
were prepared from individual brains obtained from terminally ill
C57BL mice (ME7, 139A, and 301C), VM mice (22A and 301V), and
golden hamsters (139H and 263K).
For secondary passages in C3H mice and voles, the inocula were
prepared from individual animals with terminal disease sacriﬁced
after primary transmission, or from PrP
Sc-positive mice sacriﬁced
without signs of disease, as appropriate.
Preparation of brain homogenates and bioassays. New dedicated
glassware and instruments were autoclaved at 136 8C for 1 h before
use. All samples were homogenized at 10% (w/v) concentration in
sterile physiological saline and stored at 80 8C. Groups of 10–20
bank voles or 5–15 C3H mice were injected by the intracerebral route
(20 ll) into the left cerebral hemisphere under ketamine anesthesia.
Beginning 1 mo after inoculation, voles and mice were examined
twice per week until the appearance of neurological signs, and were
then examined daily. The animals were sacriﬁced with carbon dioxide
when they reached the terminal stage of the disease. Survival time was
calculated as the interval between inoculation and sacriﬁce.
Histopathology, immunohistochemistry, and PET blot. At post-
mortem, each brain was divided into two parts by a sagittal
paramedian cut. The smaller portion was immediately frozen and
stored at 20 8C for Western blotting. The remaining part was
immersed and ﬁxed in 10% formol saline for 4 d. The brains were
trimmed at standard coronal levels, decontaminated with formic acid
for 1 h, and embedded in parafﬁn. Sections (6 lm thick each) were cut
for haematoxylin and eosin staining, immunohistochemistry, and
PET blot, randomly mixed and coded for pathological assessment.
For the construction of lesion proﬁles, vacuolar changes were
scored in nine grey-matter areas of the brain on haematoxylin and
eosin-stained sections, as described by H. Fraser and A. G. Dickinson
[49]. Vacuolation scores are derived from at least six individual voles
per group and from three individual mice per group, and are
reported as means 6 standard error of the mean.
For PrP immunohistochemistry, sections were collected on
silanized slides (Dako-Cytomation, Glostrup, Denmark). After treat-
ment at 60 8C for 24 h, sections were hydrated, pretreated with 98%
formic acid for 1 min, followed by hydrating autoclaving for 30 min
at 121 8C, and ﬁnally cooling overnight. Incubation with antibodies,
plus avidin–biotin complex treatment and revelation, were carried
out with Dako-Autostainer (Dako-Cytomation). Sections were treated
with 6% normal goat serum (Vector, Burlingame, California, United
States) in PBS for 30 min. Immunohistochemical detection of PrP was
performed with mAb SAF84 (Spi-Bio, Montigny Le Bretonneux,
France) at 2 lg/ml in PBS with 3% of normal goat serum (Vector) for
45 min. After washing with PBS, sections were treated with ABC
Complex (Vector) for 45 min and with diaminobenzidine (Dako-
Cytomation) for 7 min. Sections were counterstained with Mayer’s
haematoxylin. In each run, positive- and negative-control sections
were included.
Sections for PET blot were collected on prewetted 0.45-lm-pore
nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany).
Membranes were dried for 24 h at 55 8C. Membrane treatments,
proteinase K digestion (50 lg/ml), and immunodetection were
performed as described [50]. Monoclonal Ab SAF84 (1 lg/ml) was
used as primary antibody.
Western blot. Brain tissues were homogenized (10% w/v) in 100
mM Tris-HCl (pH 7.4) containing 2% Sarcosyl (Sigma, St. Louis,
Missouri, United States). The homogenates were incubated for 30 min
at 37 8C with gentle shaking; proteinase K (50 lg/ml; Sigma) was
added, and then the homogenates were further incubated for 1 h at
37 8C with gentle shaking. Protease treatment was stopped with 3 mM
PMSF (Sigma). Treated homogenates were denatured by adding an
equal volume of 23 NuPage sample buffer (Invitrogen, Carlsbad,
California, United States) and heating for 10 min at 90 8C. After
centrifugation at 12,000 rpm for 5 min in a microfuge, 10 ll of each
sample was loaded onto 12% bis-Tris polyacrylamide gels (Invitro-
gen). Precision Plus Strep-tagged molecular markers (Bio-Rad,
Hercules, California, United States) were loaded in each gel. After
electrophoresis and Western blotting on polyvinylidene diﬂuoride
membranes (Millipore, Bedford, Massachusetts, United States), the
blots were blocked in PBS containing 0.05% Tween 20 and 0.5% non-
fat milk powder for 1 h. PrP
Sc from voles and mice was detected with
mAb SAF84 (0.4 lg/ml) for 1 h at room temperature. When human
PrP
Sc was analyzed together with vole PrP
Sc, mAb SAF84 was used in
combination with mAb 3F4 (1:5,000). Horseradish peroxidase-
conjugated anti-mouse immunoglobulin (Pierce Biotechnology,
Rockford, Illinois, United States) was used as secondary antibody
(1:80,000 for 1 h). The membranes were developed with an enhanced
chemiluminescence method (SuperSignal Femto, Pierce Biotechnol-
ogy) and detected with the VersaDoc imaging system (Bio-Rad).
Apparent molecular weights and glycoform patterns were deter-
mined with QuantityOne software (Bio-Rad). For glycoform analysis,
values are derived from PrP
Sc of human inocula and from ﬁve
individual voles per group (means 6 standard error of the mean).
Samples that were negative by this standard protocol were further
analyzed after PrP
Sc concentration. In this case, 10% (w/v) homoge-
nates were added with 100 mM Tris-HCl (pH 7.4) containing Sarcosyl
(Sigma) to obtain a ﬁnal 5% (w/v) homogenate with 10% Sarcosyl. The
homogenates were incubated for 20 min at room temperature and
then centrifuged at 22,000 g for 20 min (TLA 100.3 rotor, Beckman
Instruments, Fullerton, California, United States). Supernatants were
added with proteinase K (50 lg/ml; Sigma) and incubated for 1 h at 37
8C with gentle shaking. Protease treatment was stopped with 3 mM
PMSF (Sigma). The treated homogenates were ultracentrifuged at
210,000 g for 40 min (TLA 100.3 rotor, Beckman Instruments), and
the pellets were resuspended in 100 ll of distilled water and
desiccated in speed-vacuum (Speed Vac Sc 110, Savant, Holbrook,
New York, United States) overnight. The ﬁnal pellets were resus-
pended in NuPage sample buffer and were analyzed by Western
blotting as above.
Supporting Information
Figure S1. Neurodegeneration and PrP
Sc Deposition in Voles
Infected with MM2 sCJD and MM1 sCJD
Found at DOI: 10.1371/journal.ppat.0020012.sg001 (1.7 MB PDF).
Accession Numbers
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bers for the genes and gene products discussed in this paper are
C57Bl mice PrP (M18070), hamsters PrP (M14054), human PrP
(M13899), VM mice PrP (M18071), vole PrP (AF367624), and sheep
PrP (M31313).
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